Blood gene signatures may help predict lymphoma treatment response: full analysis

A new study from Tufts University suggests that a simple blood draw may help predict which dogs with diffuse large B-cell lymphoma will do well on treatment, and which may relapse early. In pet dogs enrolled in a chemoimmunotherapy clinical trial, researchers found that blood-based immune gene signatures tracked with survival outcomes, raising the possibility of a more personalized approach to canine lymphoma care. (pmc.ncbi.nlm.nih.gov)

The study builds on a broader Tufts effort to use naturally occurring canine lymphoma as both a veterinary clinical problem and a translational model for human disease. In an earlier analysis from the same trial, investigators examined lymph node aspirates collected before treatment and found that baseline tumor gene-expression patterns differed between dogs with better and worse outcomes, with some markers appearing to predict response to specific treatment combinations. That earlier work underscored the heterogeneity of canine diffuse large B-cell lymphoma and the limits of a one-size-fits-all treatment strategy. (pubmed.ncbi.nlm.nih.gov)

In the newer paper, the team shifted from tumor tissue to peripheral blood mononuclear cells collected over time. Using the NanoString Canine IO panel, they reported that increases in interferon-stimulated genes, along with genes such as CCR9, CD209, CMKLR, and DDX58, were associated with shorter survival, defined in the study as less than 400 days. By contrast, CD1E and CCL14 were elevated after immunotherapy in long-term survivors. The authors also identified TBHD, NPNT, and ISG20 as early-treatment markers that were higher at day 7 in dogs with shorter survival, and they said they developed qPCR assays for those targets as a step toward point-of-care testing. (pmc.ncbi.nlm.nih.gov)

The dogs in the trial received a caninized anti-CD20 monoclonal antibody, described by the authors as a rituximab equivalent, plus low-dose doxorubicin and one of three small-molecule agents: RV1001, KPT-9274, or TAK-981. According to the paper, the regimens were well tolerated and had previously shown median survival times comparable to or better than CHOP alone, though outcomes still varied meaningfully across individual dogs. That variability is what makes a blood-based predictor attractive: it could help clinicians identify poor responders sooner, without repeated invasive sampling. (pmc.ncbi.nlm.nih.gov)

Outside this specific study, the findings land in a veterinary oncology landscape that is already moving toward liquid biopsy and blood-based monitoring. Reviews and recent clinical reports have highlighted growing interest in non-invasive cancer detection, prognosis, and recurrence monitoring in dogs, including lymphoma. But most currently discussed liquid-biopsy approaches in practice focus on cell-free DNA rather than immune-cell transcriptional signatures, so the Tufts work adds a different and potentially complementary layer of biologic information. (todaysveterinarypractice.com)

There does not yet appear to be broad published outside commentary on this specific paper, but the authors themselves are careful in how they frame it. They describe the findings as “proof of principle” that interrogating peripheral blood mononuclear cells can help predict early relapse and identify poor responders. They also note that some markers, including CCL14, have shown mixed prognostic associations across different cancers, which reinforces that these signatures will need disease-specific validation before they can be used confidently in practice. (pmc.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, this is less about an immediately deployable test and more about where lymphoma management may be heading. If validated, serial blood-based immune profiling could help oncologists and referring veterinarians refine prognosis, counsel pet parents earlier, and decide when a dog may need closer monitoring or a treatment change. It also supports the broader trend toward precision oncology in companion animals, where treatment decisions are increasingly informed by molecular and immune features rather than histology alone. At the same time, the study was relatively small, tied to a specific trial population, and not yet practice-changing. (pmc.ncbi.nlm.nih.gov)

What to watch: The key next steps are external validation, assay simplification, and evidence that using these blood markers actually improves decision-making or outcomes in routine practice. Watch for follow-up studies testing the qPCR-based markers in larger cohorts, comparisons with more established liquid-biopsy platforms, and whether any of these signatures can be integrated into real-world monitoring protocols for dogs with lymphoma. (pmc.ncbi.nlm.nih.gov)